Literature DB >> 10616580

Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin.

I R Whittle1, G Malcolm, D I Jodrell, M Reid.   

Abstract

The objective of this paper was to determine the time course and extent of platinum uptake into human malignant glioma tissue. An intraoperative, intravenous infusion of carboplatin was given to nine patients (seven glioblastoma and two anaplastic glioma) undergoing tumour excision. Carboplatin dosage was calculated individually to achieve a target systemic free carboplatin exposure. Tumour and peritumoural tissue was harvested at timed intervals following carboplatin administration. Plasma and tumour platinum concentrations were measured by graphite furnace flameless atomic absorption spectrophotometry. Histological examination was also performed on a piece of each tissue sample. The mean carboplatin dose administered was 783, SEM 56 mg (range 485-903). Plasma pharmacokinetics showed a typical elimination curve. The mean peak plasma platinum concentration was 44, SEM 5 micrograms/ml (range 27-74). The mean total elemental plasma platinum area under the curve (AUC) was 9.0, SEM 1.4 mg/ml/min. Platinum was detected in 61 tumour samples, the mean peak concentration being 13 SEM 2 micrograms/g (range 5-21). Platinum was also detected in peritumoural brain and necrotic tumour. No correlation was apparent between the degree of necrosis in each tumour specimen and tumour platinum concentration. Platinum concentrations achieved in tumour were similar to levels that would be cytotoxic for glioma cells in vitro. The results of this study have implications for future studies using capillary permeability modifying agents as adjuncts to brain tumour chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10616580     DOI: 10.1080/02688699943871

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  11 in total

1.  An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma.

Authors:  Edward White; Alison Bienemann; John Pugh; Emma Castrique; Marcella Wyatt; Hannah Taylor; Alan Cox; Cameron McLeod; Steven Gill
Journal:  J Neurooncol       Date:  2012-04-04       Impact factor: 4.130

2.  Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Authors:  Todd W Miller; Nicole A Traphagen; Jing Li; Lionel D Lewis; Beatriz Lopes; Ashok Asthagiri; Johanna Loomba; Jenny De Jong; David Schiff; Sohil H Patel; Benjamin W Purow; Camilo E Fadul
Journal:  J Neurooncol       Date:  2019-08-09       Impact factor: 4.130

Review 3.  Tissue concentration of systemically administered antineoplastic agents in human brain tumors.

Authors:  Marshall W Pitz; Arati Desai; Stuart A Grossman; Jaishri O Blakeley
Journal:  J Neurooncol       Date:  2011-03-12       Impact factor: 4.130

Review 4.  Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol.

Authors:  Saskia L Gooskens; Norbert Graf; Rhoikos Furtwängler; Filippo Spreafico; Christophe Bergeron; Gema L Ramírez-Villar; Jan Godzinski; Christian Rübe; Geert O Janssens; Gordan M Vujanic; Ivo Leuschner; Aurore Coulomb-L'Hermine; Anne M Smets; Beatriz de Camargo; Sara Stoneham; Harm van Tinteren; Kathy Pritchard-Jones; Marry M van den Heuvel-Eibrink
Journal:  Nat Rev Urol       Date:  2018-02-27       Impact factor: 14.432

Review 5.  The blood-tumour barrier in cancer biology and therapy.

Authors:  Patricia S Steeg
Journal:  Nat Rev Clin Oncol       Date:  2021-07-12       Impact factor: 66.675

6.  New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery.

Authors:  Benjamin S Carson; Qingze Wu; Betty Tyler; Lindsey Sukay; Ratul Raychaudhuri; Francesco DiMeco; Richard E Clatterbuck; Alessandro Olivi; Michael Guarnieri
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

Review 7.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Authors:  Jann N Sarkaria; Leland S Hu; Ian F Parney; Deanna H Pafundi; Debra H Brinkmann; Nadia N Laack; Caterina Giannini; Terence C Burns; Sani H Kizilbash; Janice K Laramy; Kristin R Swanson; Timothy J Kaufmann; Paul D Brown; Nathalie Y R Agar; Evanthia Galanis; Jan C Buckner; William F Elmquist
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

8.  Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate.

Authors:  R J Strege; Y J Liu; A Kiely; R M Johnson; E M Gillis; P Storm; B S Carson; G I Jallo; M Guarnieri
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

9.  Convection-enhanced drug delivery: prospects for glioblastoma treatment.

Authors:  Neil U Barua; Steven S Gill
Journal:  CNS Oncol       Date:  2014

10.  In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.

Authors:  D M Ashley; C D Riffkin; M M Lovric; T Mikeska; A Dobrovic; J A Maxwell; H S Friedman; K J Drummond; A H Kaye; H K Gan; T G Johns; C J Hawkins
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.